Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
Clinical trial NCT01196728 · COMPLETED
Trial details
- NCT number
- NCT01196728
- Sponsor
- CellMed AG, a subsidiary of BTG plc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-09-01
- Primary completion
- 2010-11-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.